Skip Navigation
Pipeline

Black Diamond’s Unique Approach

Target
Candidate / Indication
Discovery
Optimization
IND-Enabling
Phase 1
Phase 2
Phase 3
EGFR

BDTX-1535

GBM, NSCLC ± CNS tumors
  • Discovery CompletedDiscovery % Completed
  • Optimization CompletedOptimization % Completed
  • IND-Enabling CompletedIND-Enabling % Completed
  • Phase 1 10% Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Phase 1

BDTX-1535 is designed to be a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).

BRAF

BDTX-4933

Targeted solid tumors ± CNS tumors
  • Discovery CompletedDiscovery % Completed
  • Optimization CompletedOptimization % Completed
  • IND-Enabling 30% Completed
  • Phase 1 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
IND-Enabling

BDTX-4933 is designed to target all the MasterKey mutations comprised of Class I, Class II, and Class III mutations while avoiding paradoxical activation by inhibiting dimerized RAF kinase and to be brain penetrant to treat CNS diseases.

FGFR

Undisclosed

Multiple solid tumors
  • Discovery CompletedDiscovery % Completed
  • Optimization 30% Completed
  • IND-Enabling % Completed
  • Phase 1 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Optimization

BDTX FGFR program compounds are MasterKey inhibitors of allosteric FGFR2/3 mutations with selectivity versus FGFR1 and activity against clinically relevant resistance mutations.

Undisclosed

Undisclosed

Multiple solid tumors
  • Discovery CompletedDiscovery % Completed
  • Optimization 30% Completed
  • IND-Enabling % Completed
  • Phase 1 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Optimization

Utilizing our proprietary MAP discovery engine, we are developing a pipeline of orally available, potent, and selective drug candidates that target a range of driver mutations in cancer. We term these MasterKey inhibitors, which are designed for the treatment of MasterKey mutations across a range of tumor types.

Our disclosed MasterKey programs are brain-penetrant small molecules that target groups of epidermal growth factor receptor (EGFR) mutants in GBM and NSCLC in addition to Class I, II and III mutants in BRAF. We are also progressing our earlier stage pipeline programs targeting groups of MasterKey mutations in targets relevant to cancer and/or rare genetic diseases. These programs, which we have developed using our MAP discovery engine, are currently progressing through lead optimization.